The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Meritxell Sabidó(Merck KGaA, Darmstadt (Germany)), Nicholas Moore(American Sports Medicine Institute), Merja Soilu‐Hänninen(University of Turku), Jens Kühle(University of Basel), Jan Hillert, Joseph R. Berger(University of Pennsylvania), Stig Wergeland(Haukeland University Hospital), Aida Aydemir(Merck KGaA, Darmstadt (Germany)), Melinda Magyari(University of Copenhagen), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Irene D. Bezemer(Leiden University Medical Center)
Cited by 7
Related Papers
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
|Science|2022|2k
Multiple Sclerosis Severity Score
|Neurology|2005|957
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
|Nature Medicine|2019|948
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
|Nature Reviews Neurology|2022|809